PL1638529T3 - Kompozycja doustna o przedłużonym uwalnianiu - Google Patents

Kompozycja doustna o przedłużonym uwalnianiu

Info

Publication number
PL1638529T3
PL1638529T3 PL04776663T PL04776663T PL1638529T3 PL 1638529 T3 PL1638529 T3 PL 1638529T3 PL 04776663 T PL04776663 T PL 04776663T PL 04776663 T PL04776663 T PL 04776663T PL 1638529 T3 PL1638529 T3 PL 1638529T3
Authority
PL
Poland
Prior art keywords
release composition
oral extended
oral
extended
release
Prior art date
Application number
PL04776663T
Other languages
English (en)
Inventor
Boyong Li
Avinash Nangia
Monte Browder
Original Assignee
Andrx Pharmaceuticals, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals, Llc. filed Critical Andrx Pharmaceuticals, Llc.
Publication of PL1638529T3 publication Critical patent/PL1638529T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04776663T 2003-06-16 2004-06-16 Kompozycja doustna o przedłużonym uwalnianiu PL1638529T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47891503P 2003-06-16 2003-06-16

Publications (1)

Publication Number Publication Date
PL1638529T3 true PL1638529T3 (pl) 2017-03-31

Family

ID=33539127

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04776663T PL1638529T3 (pl) 2003-06-16 2004-06-16 Kompozycja doustna o przedłużonym uwalnianiu

Country Status (6)

Country Link
US (2) US7476403B2 (pl)
EP (3) EP2535042A1 (pl)
AU (1) AU2004249211A1 (pl)
CA (3) CA2675724C (pl)
PL (1) PL1638529T3 (pl)
WO (1) WO2004112711A2 (pl)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6565882B2 (en) * 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
TW200526274A (en) * 2003-07-21 2005-08-16 Smithkline Beecham Plc Pharmaceutical formulations
JP2006528185A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
WO2005016311A1 (en) * 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
US7943585B2 (en) * 2003-12-22 2011-05-17 Sandoz, Inc. Extended release antibiotic composition
CA2550983C (en) * 2003-12-24 2013-09-17 Advancis Pharmaceutical Corporation Enhanced absorption of modified release dosage forms
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation
WO2006014427A1 (en) * 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
CA2592605C (en) * 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0516168D0 (en) * 2005-08-05 2005-09-14 Cambridge Lab Ireland Ltd Pharmaceutical compounds
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
WO2007123883A2 (en) * 2006-04-17 2007-11-01 Actavis Group Ptc Ehf Oral dosage formulations and methods of preparing the same
US20070243245A1 (en) * 2006-04-17 2007-10-18 Actavis Group Ptc Hf Oral Dosage Formulations, Methods of Preparing the Same, and Methods of Reducing Food Effects on Drug Release
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
WO2011019956A2 (en) 2009-08-12 2011-02-17 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
CN101439025B (zh) * 2008-12-31 2011-05-11 江苏大学 一种水飞蓟素高效长效制剂及其制法
CN101444503B (zh) * 2008-12-31 2011-02-02 江苏大学 一种水飞蓟宾高效长效制剂及其制法
EP2283824B1 (en) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US9550780B2 (en) 2012-09-18 2017-01-24 Auspex Pharmaceuticals, Inc. Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
JP6362601B2 (ja) 2012-09-18 2018-07-25 オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 小胞モノアミン輸送体２の重水素化ベンゾキノリン阻害剤の製剤薬物動態
EP2958577A2 (en) 2013-02-25 2015-12-30 Synergy Pharmaceuticals Inc. Guanylate cyclase receptor agonists for use in colonic cleansing
CA2926691A1 (en) 2013-10-10 2015-04-16 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
AU2014357518A1 (en) 2013-12-03 2016-06-09 Auspex Pharmaceuticals, Inc. Methods of manufacturing benzoquinoline compounds
PL3265085T3 (pl) 2015-03-06 2022-11-07 Auspex Pharmaceuticals, Inc. Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3402804A1 (en) 2016-01-11 2018-11-21 Synergy Pharmaceuticals Inc. Formulations and methods for treating ulcerative colitis
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US4064230A (en) * 1966-04-25 1977-12-20 Schmid Laboratories, Inc. Polyenic macrolide compositions
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
JPS60163823A (ja) 1984-02-03 1985-08-26 Taisho Pharmaceut Co Ltd 経口投与製剤
DE3583799D1 (de) * 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
EP0418596A3 (en) * 1989-09-21 1991-10-23 American Cyanamid Company Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5009895A (en) 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
KR0168715B1 (ko) 1992-11-30 1999-01-15 밋첼 아이. 커시너 맛을 차단하는 약제학적 조성물
US5393765A (en) * 1993-12-13 1995-02-28 Hoffmann-La Roche Inc. Pharmaceutical compositions with constant erosion volume for zero order controlled release
DE69530973T2 (de) 1994-02-16 2004-05-19 Abbott Laboratories, Abbott Park Verfahren zur herstellung feinteiliger pharmazeutischer formulierungen
DE69524214T3 (de) * 1994-05-06 2008-05-15 Pfizer Inc. Azithromycin enthaltende arzneiverabreichungsformen mit gesteuerter wirkstoffabgabe
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
WO1998056357A1 (en) * 1995-12-19 1998-12-17 Abbott Laboratories A controlled release formulation for poorly soluble basic drugs
CA2259420C (en) 1996-07-05 2007-09-18 Biotica Technology Limited Erythromycins and process for their preparation
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
ATE302597T1 (de) * 1997-06-06 2005-09-15 Depomed Inc Im magen verweilende orale dosierungsformen von wasserlöslichen arzneistoffen mit kontrollierter freisetzung
ES2234139T3 (es) * 1997-08-11 2005-06-16 Alza Corporation Forma de dosificacion de un agente activo de liberacion prolongada adaptada para la retencion gastrica.
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
MX339071B (es) * 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
NZ518739A (en) 1999-11-02 2004-12-24 Depomed Inc Pharmacological inducement of the fed mode for enhanced drug administration to the stomach
US6730320B2 (en) * 2000-02-24 2004-05-04 Advancis Pharmaceutical Corp. Tetracycline antibiotic product, use and formulation thereof
US6642276B2 (en) * 2001-10-01 2003-11-04 M/S Ind-Swift Limited Controlled release macrolide pharmaceutical formulations
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040043073A1 (en) * 2002-06-14 2004-03-04 Chih-Ming Chen Pharmaceutical compositions for drugs having pH-dependent solubility
US7063862B2 (en) * 2003-06-03 2006-06-20 Biokey, Inc. Pharmaceutical composition and method for treating
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
EP1732518A1 (en) * 2004-03-24 2006-12-20 Lupin Ltd. Clarithromycin extended release formulation

Also Published As

Publication number Publication date
CA2673334C (en) 2013-11-12
US20090124563A1 (en) 2009-05-14
EP1638529A4 (en) 2010-01-06
CA2529746A1 (en) 2004-12-29
US8628797B2 (en) 2014-01-14
WO2004112711A3 (en) 2005-05-19
CA2529746C (en) 2010-08-03
WO2004112711A2 (en) 2004-12-29
US20050064034A1 (en) 2005-03-24
EP1638529B1 (en) 2016-08-10
EP2529730A1 (en) 2012-12-05
US7476403B2 (en) 2009-01-13
AU2004249211A1 (en) 2004-12-29
CA2675724A1 (en) 2004-12-29
EP1638529A2 (en) 2006-03-29
EP2535042A1 (en) 2012-12-19
CA2673334A1 (en) 2004-12-29
CA2675724C (en) 2012-12-04

Similar Documents

Publication Publication Date Title
EP1638529A4 (en) ORAL COMPOSITION WITH PROLONGED RELEASE
PL365518A1 (pl) Kompozycja doustna
GB0305941D0 (en) Composition
GB0302738D0 (en) Composition
GB0324918D0 (en) Composition
AU2003252683A8 (en) Composition for oral use
GB0324897D0 (en) Composition
GB0322033D0 (en) Composition
GB0325383D0 (en) Oral formulations
MY145151A (en) Composition
EP1600445A4 (en) CURATIVE PREPARATION
AU2003230434A8 (en) Composition for enhancing oral health
GB0309317D0 (en) Composition
IL173743A0 (en) Oral itrazole compositions
GB0324295D0 (en) Composition
GB0326815D0 (en) Composition
GB0306312D0 (en) Composition
GB0406393D0 (en) Oral composition
GB0301869D0 (en) Composition
GB0311465D0 (en) Composition
GB0406392D0 (en) Oral composition
GB2390303B (en) Oral compositions
GB0222651D0 (en) Dental compositions
GB0323203D0 (en) Composition II
GB0324168D0 (en) Composition II